X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
huMNC2-CAR22 bears the “1XX” mutations in the T cell’s CD3-z signaling domain, targeting MUC1*, the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
Lead Product(s): huMNC2-CAR22
Therapeutic Area: Oncology Product Name: huMNC2-CAR22
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Minerva Biotechnologies has licensed from Memorial Sloan Kettering Cancer Center (MSK) “1XX” technology for use with Minerva’s proprietary anti-MUC1* antibodies to increase CAR T cell persistence in patients.
Lead Product(s): huMNC2-CAR44 CAR T cells
Therapeutic Area: Oncology Product Name: huMNC2-CAR44
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: Memorial Sloan Kettering Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
